Blood Test Combines Cutting-Edge Genomics and AI to Identify Persistent or Recurrent Cancer
Posted on 26 Oct 2021
The world’s first whole-genome cancer intelligence platform combines artificial intelligence (AI) pattern recognition and whole-genome sequencing to provide rapid and specific detection of residual disease that is up to 100x more sensitive than competing technologies, while only using small samples of blood (1-2mL).
C2i Genomics (New York, NY, USA) has combined cutting-edge genomics and sophisticated AI to provide the world’s first whole-genome cancer intelligence platform, transforming the way cancer is monitored and treated. The company’s novel approach to detecting minimal residual disease (MRD) leverages the entire three billion base pairs of the genome using whole genome pattern recognition.
Across the entire genome, the technology identifies the genetic pattern of a patient’s cancer using thousands of data points and our proprietary computation and AI methods. The technology allows for significantly higher sensitivity, 100X more than any other alternative, while only using small samples of blood (1-2mL). The large genomic signature allows accurate and robust tracking of the tumor progression as it evolves during the patient treatment and follow-up period. The technology also eliminates the need to develop a patient-specific assay, enabling high performance monitoring with reduced complexity and rapid turnaround.
The technology has been validated with more than 1000 samples processed in longitudinal studies with top global clinical centers, C2i has now established partnerships with leading cancer sequencing centers across the world, with active clinical trials conducted at the US, EU and Asia, covering a variety of solid cancer types. In its latest tie-up, C2i has entered into a strategic partnership with NuProbe Global (Houston, TX, USA), a genomics and molecular diagnostics company specializing in ultrasensitive sequencing panels. The strategic alliance will power high-impact pharmaceutical and diagnostic services, leveraging C2i’s AI-powered cancer intelligence platform across NuProbe’s chemistry products and sequencing networks in both China and the US.
As part of this collaboration, NuProbe and C2i will engage in the co-development of chemistry and software products that will expand the traditional whole-genome library preparation to include additional signal enrichment for cancer hotspots, Microsatellite instability (MSI) and fusions. The combined whole-genome signal integration and ultra-sensitive interception of cancer hotspots, MSI and fusions will significantly improve cancer screening and MRD monitoring clinical performance. The combined products will be commercialized for pharma and diagnostic services in China through the NuProbe sequencing lab network and for the rest of the world through NuProbe’s chemistry kit and C2i’s cloud-based cancer intelligence platform.
“C2i Genomics’ advanced cloud platform and state-of-the-art algorithms provide great synergy to NuProbe’s ultra-sensitive sequencing technology,” said David Zhang, co-founder and General Manager of NuProbe USA. “Combining the unique capabilities of both companies will provide a new technology and simplified workflow for more precise cancer screening and monitoring, access to greater insights and potential to develop therapies that mirror the dynamics of cancer.”
“C2i is built on the foundations of innovation, breaking global boundaries and changing the status quo of cancer management and we found NuProbe to be a natural partner to our vision of technology innovation and global product expansion,” explained Asaf Zviran, co-founder and CEO of C2i Genomics. “Together, we’re setting a new standard for cancer diagnosis, research and care, globally.”
Related Links:
C2i Genomics
NuProbe Global
